Covid-19 Statement

The health and safety of our patients, our employees and their families are Ferring’s number one priority. As the situation regarding COVID-19 (novel coronavirus disease) is evolving rapidly, Ferring is committed to following appropriate global, regional and local medical authority guidance to prevent infection spread and to keep patients, our employees and their families safe.

Working in the healthcare sector, we are in the forefront to apply all necessary measures to minimise the spread of the Coronavirus (Covid-19) to protect our employees, customers and patients.

Therefore, Ferring Pharmaceuticals (UK) Ltd. have taken the following decisions:

• All our sales representatives, medical staff and brand managers stopped all visits to hospitals  and clinics from Friday 20th March 2020

• Ferring sales representatives, medical staff and brand managers will be available to contact remotely via phone or email

In addition to policies to protect our employees and prevent infection spread, we have also put in place plans to avoid disruption in manufacturing and ensure continuity of supply of our treatments to doctors and patients around the world.  However, we unfortunately cannot rule out a future impact on our business as the situation is rapidly evolving.

Our thoughts are with the people and families affected by COVID-19 around the world, including our patients and those working tirelessly to address the pandemic.

We remain committed to supporting our patients and stakeholders during the COVID-19 outbreak.

If you are personally impacted by this situation and have questions for Ferring, please email customer.services@ferring.com or call 0800 111 4125 to get in touch with our teams.

For adverse event reporting please contact medical.uk@ferring.com. Alternatively, please call 0800 111 4126.